PainReform
PRFXPRFX · Stock Price
Historical price data
Overview
PainReform's mission is to transform post-operative care by developing proprietary, extended-release formulations of established therapeutics to reduce opioid reliance. Its core achievement is the advancement of PRF-110 into Phase 3 for bunionectomy pain, with positive Phase 2 data in hernia repair. The company's strategy leverages a lower-risk reformulation approach to create new intellectual property and has recently expanded its scope to include AI for solar energy optimization under the new PRF Technologies umbrella.
Technology Platform
Proprietary platform for creating sustained-release formulations of established drugs, utilizing polymer-based and oil-based delivery systems for localized, extended therapeutic effect.
Pipeline
4| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Ropivacaine | Bunion | Phase 3 | |
| PRF110- oily solution (Ropivacaine) | Post Operative Pain | Phase 2 | |
| PRF110 | Post Operative Pain | Phase 2 | |
| PRF-108 + Placebo + Ropivacaine + PRF-110 | Pain | Phase 1/2 |
Opportunities
Risk Factors
Competitive Landscape
PRF-110 competes in the long-acting local anesthetic market against established products like Exparel (Pacira). The company's reformulation strategy is common, requiring superior clinical data to gain market share. Its dual biotech/energy tech model lacks clear peers.
